The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.
Semaglutide proves a game-changer for kidney and heart health in diabetes patients
- Post author:
- Post published:June 25, 2024
- Post category:uncategorized